The White House will not move forward with a proposed rule to eliminate manufacturer rebates, delivering a defeat to the industry, which had lobbied heavily in favor of the policy change. It is the second big proposal from the Department of Health and Human Services blueprint on drug pricing to go up in smoke this month after a federal judge struck down the Trump Administration's rule requiring the disclosure of drug prices in TV ads.
Unlike with the direct-to-consumer (DTC) ad policy, industry advocated in favor of eliminating rebates, the payments it makes to payers...
